View Post

Which Studies Will be Practice Changing in Metastatic Breast Cancer?

In In The News by Barbara Jacoby

By: Greg Lau From: medpagetoday.com Promising findings from various clinical trials at the San Antonio Breast Cancer Symposiumopens in a new tab or window (SABCS) have the metastatic breast cancer research community excited about the future of treatment. In this exclusive MedPage Today video, Jason Aboudi Mouabbi, MD, assistant professor in the Department of Breast Medical Oncology at the University …

View Post

SABCS Trials Show Improved Outcomes in Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com Oral selective estrogen receptor downregulators, or SERDs as they’re known, have now come into the market and are coming out of trials, I should say, and are being tested in phase II and now in phase III trials. The first one to report mature data from the phase III trial was elacestrant [Orserdu], which was …

View Post

Metastatic Breast Cancer Costs Have Increased, Vary by Subtype

In In The News by Barbara Jacoby

By: Nancy A. Melville From: medscape.com An up-to-date economic evaluation of the costs associated with metastatic breast cancer in the United States revealed significant differences in costs on the basis of cancer subtypes and the increasing availability of novel, often pricier, treatment options. Overall, researchers found that the mean Medicare costs of anticancer and supportive therapy was highest for hormone …

View Post

OS Advances Gather Steam in Breast Cancer

In In The News by Barbara Jacoby

By: Anita T. Shaffer From: onclive.com The treatment of patients with breast cancer is making noteworthy strides in several clinical settings, with recent trial results showing overall survival improvements for advanced and metastatic disease. The treatment of patients with breast cancer is making noteworthy strides in several clinical settings, with recent trial results showing overall survival (OS) improvements for advanced …

View Post

Breast cancer awareness campaigns too often overlook those with metastatic breast cancer – here’s how they can do better

In In The News by Barbara Jacoby

From: theconversation.com s there anyone who isn’t aware of breast cancer? Since 1985, cancer-related nonprofits, along with pharmaceutical firms and other businesses, have sponsored an international campaign to observe October as “Breast Cancer Awareness Month.” During these weeks, the public is bombarded with awareness and education messaging featuring the campaign’s symbol, a pink ribbon. A wave of pink products typically …

View Post

Cost Paramount When Choosing Metastatic Breast Cancer Treatment

In In The News by Barbara Jacoby

By: Sharon Worcester, MA From: medscape.com While efficacy and quality-of-life outcomes are similar across commonly used treatments for endocrine-refractory or triple-negative metastatic breast cancer, the costs of these agents vary widely, a recent analysis reveals. Notably, the authors found that using standard chemotherapy agents in specific sequences can help reduce overall costs and improve the value of care. Given “razor …

View Post

Link Between Metastatic Breast Cancer and Anemia

In In The News by Barbara Jacoby

From: clevelandclinic.org Treatments like chemotherapy and radiation can cause your red blood cell levels to decrease As the most advanced stage of breast cancer, metastatic breast cancer develops when cancer cells have spread to other parts of your body like your lungs, bones, brain or liver. There’s a whole host of symptoms you may experience as you go through your …

View Post

VTE rate with abemaciclib higher in real-world setting among patients with breast cancer

In In The News by Barbara Jacoby

By: Jennifer Southall From: healio.com Abemaciclib resulted in an approximately twofold higher venous thromboembolism rate in a real-world setting compared with clinical trials among patients with metastatic breast cancer, according to study results published in Cancer. Researchers also reported a significantly higher risk for death among patients who developed thrombosis. Rationale and methods The potential risk for VTE associated with …

View Post

FDA Grants Priority Review to NDA for Elacestrant in ER+/HER2- Advanced or mBC

In In The News by Barbara Jacoby

By: Nichole Tucker astaastFrom: targetedonc.com Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review. The FDA has accepted a new drug application for the selective estrogen receptor degrader, elacestrant, and granted it priority review …

View Post

How Low Can We Go? Metastatic Breast Cancer Enters a New Era of HER2 Classification

In In The News by Barbara Jacoby

By: Brittany Lovely From: onclive.com Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression. Data from DESTINY-Breast04 (NCT03734029) presented at the 2022 ASCO Annual Meeting thrust the topic of defining HER2-low metastatic breast …